CGT · 혈액암 (AML/ALL)

360개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved360 programs
CGTStandard DatabasestaleYake Biotechnology Ltd.Phase 2

CAR-T cells targeting CD19 and CD22 (CAR-T cells targeting CD19 and CD22)

B-Cell Acute Lymphoblastic Leukemia, Adult · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Active
CGTStandard DatabasestaleBOE Technology Group Co., Ltd.Phase 2

NK cells + PD- (NK cells + PD-, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy)

NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer · NSCLC (Advanced Non-small Cell Lung Canc

#NSCLCAdvancedNon-smallCellLungCa#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 30Status Recruiting
CGTStandard DatabasestaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
CGTLimited DatastaleHrain Biotechnology Co., Ltd.Preclinical

anti-CD19-CAR vector-transduced T cells (anti-CD19-CAR vector-transduced T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 30Status Active
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Phase 1

anti-CD19/CD22 CAR-T cells (anti-CD19/CD22 CAR-T cells)

MRD-positive; Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 28Status Active
CGTStandard DatabasestaleNkarta, Inc.Phase 2

allogeneic, donor-derived NK cells (allogeneic, donor-derived NK cells)

Acute Myelogenous Leukemia · Acute Myelogenous Leukemia

#AcuteMyelogenousLeukemia#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 25Status Discontinued
CGTLimited DatastaleIntrexon CorporationPhase 1

CD33-CAR-T Cell Infusion (CD33-CAR-T Cell Infusion)

Hematopoietic/Lymphoid Cancer; Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 20Status Discontinued
CGTStandard DatabasestaleCelgenePhase 3

JCAR017 (JCAR017)

Lymphoma, Non-Hodgkin · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#CGT#Phase3#cell-gene-therapy#CAR-T+4
Trials 20Status Active
CGTLimited DatastaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 17Status Discontinued
CGTLimited DatastaleBeam Therapeutics Inc.Phase 1

BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201))

T-Cell Acute Lymphoblastic Leukemia/Lymphoma · T-Cell Acute Lymphoblastic Leukemia/Lymp

#T-CellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 16Status Recruiting
CGTLimited DatastaleDutch Cancer SocietyPhase 1

UCB-NK cells (UCB-NK cells)

Recurrent Ovarian Carcinoma; Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma

#RecurrentOvarianCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 16Status Active
CGTLimited DatastaleLiping DouPhase 2

CD22/CD19 Dual-Target CAR-T Cells (CD22/CD19 Dual-Target CAR-T Cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 15Status Recruiting
CGTLimited DatastaleNkarta, Inc.Phase 1

NKG2D CAR-NK (NKG2D CAR-NK)

Refractory Metastatic Colorectal Cancer · AML

#AML#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 14Status Active
CGTLimited DatastaleAffiliated Hospital to Academy …Phase 2

Anti-CD22-CAR-transduced T cells (Anti-CD22-CAR-transduced T cells)

Leukemia; Lymphoma · CD22

#CD22#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 13Status Active
CGTLimited DatastaleStephan Grupp MD PhDPhase 2

huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 13Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Relapsed and/or Refractory Acute Myeloid Leukemia; High Risk Hematologic Malignancies · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Active
CGTLimited DatastaleBiohaven Pharmaceuticals, Inc.Phase 1

CIML-NK cell therapy (CIML-NK cell therapy)

Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 12Status Recruiting
CGTLimited DatastaleShenzhen Institute for Innovati…Phase 2

Drugs and anti-CD19 CAR transduced T cells (Drugs and anti-CD19 CAR transduced T cells)

Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 12Status Active
CGTStandard DatabasestaleVyriad, Inc.Phase 2

Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter (Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter)

Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Clear Cell Adenocarcinoma

#FallopianTubeClearCellAdenocarci#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 12Status Active
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART19A (ThisCART19A)

Non-Hodgkin's Lymphoma · Allogeneic, CAR-T, Protein Sequestration

#AllogeneicCAR-TProteinSequestrat#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 12Status Recruiting

3 / 18 pages

← PreviousNext →